J. Bilezikian

Hypercalciuria: its value as a predictive risk factor for nephrolithiasis in asymptomatic primary hyperparathyroidism?

C. Marcocci, F. Cetani, M. Scalese, 2019, Journal of Endocrinological Investigation.

Dose-response study of alendronate sodium for the treatment of cancer-associated hypercalcemia.

R. Warrell, A. F. Stewart, B. Gertz, 1993, Journal of Clinical Oncology.

CLINICAL CASE SEMINAR Osteoporosis: An Unusual Presentation of Childhood Crohn’s Disease*

W. Berdon, M. Harbison, M. Thearle, 2022 .

Differential diagnosis, causes, and management of hypercalcemia.

J. Bilezikian, F. Chan, S. Thys-Jacobs, 1997, Current problems in surgery.

Consensus statement from 2nd International Conference on Controversies in Vitamin D

C. Marcocci, A. Formenti, B. Dawson-Hughes, 2020, Reviews in Endocrine and Metabolic Disorders.

Towards a diagnostic and therapeutic consensus in male osteoporosis

J. Kaufman, J. Kanis, S. Khosla, 2011, Osteoporosis International.

Revisiting the endocrine and metabolic manifestations of COVID-19 two years into the pandemic

A. Giustina, J. Bilezikian, 2022, Reviews in Endocrine and Metabolic Disorders.

Shinall Differentiating familial hypocalciuric hypercalcemia from primary hyperparathyroidism.

Mc, S. Silverberg, J. Bilezikian, 2003 .